Arabic Gum-Absorption Study
- Conditions
- Bioavailability
- Interventions
- Dietary Supplement: menaquinone-7 from arabic gum capsulesDietary Supplement: menaquinone-7 from casein capsulesDietary Supplement: menaquinone-7 from linseed oil capsules
- Registration Number
- NCT00858767
- Lead Sponsor
- Maastricht University Medical Center
- Brief Summary
Previous studies have indicated that menaquinone-7 (MK-7) is the most effective form of vitamin K. The Japanese soya product natto is one of the richest food sources of MK-7, but its taste is not appreciated by the Western society. For this reason, the active biological compound has been manufactured as enriched oil or casein (≈80% of proteins in cow's milk)-enriched powder. However, cow's milk allergy is the most common cause of food allergy affecting a minimum of 2-3% of infants. The investigators will therefore compare this protein-delivery system to an alternative delivery system (Arabic gum; 98% polysaccharides). To compare the difference between powder and oil as MK-7 delivery vehicle, the investigators will also test the efficacy of enriched linseed oil.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 69
- Healthy men and women aged between 20 and 40 y
- Normal body weight and height (BMI <30 kg/m2)
- Stable body weight (weight gain or loss <3 kg in past 3 mo)
- Caucasian race
- Written consent to take part in the study
- Low vitamin K status
- (A history of) metabolic or gastrointestinal diseases
- Chronic degenerative and/or inflammatory diseases
- Abuse of drugs and/or alcohol
- Use of corticosteroids
- Use of oral anticoagulants
- (A history of) soy allergy
- Use of vitamin K-containing multivitamins or vitamin K supplements
- Anaemia
- Blood donation or participation in another study within one month before the study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 2 menaquinone-7 from arabic gum capsules 2 arabic gum capsules per day existing of 90 µg menaquinone-7 per day for 8 weeks 1 menaquinone-7 from casein capsules 2 casein capsules per day existing of 90 µg menaquinone-7 per day for 8 weeks 3 menaquinone-7 from linseed oil capsules 2 linseed capsules existing of 90 µg menaquinone-7 per day for 8 weeks
- Primary Outcome Measures
Name Time Method serum level menaquinone-7 8 weeks
- Secondary Outcome Measures
Name Time Method plasma level of biochemical markers carboxylated matrix-Gla protein, undercarboxylated matrix-Gla protein, carboxylated osteocalcin, undercarboxylated osteocalcin 8 weeks
Trial Locations
- Locations (1)
VitaK BV /University of Maastricht
🇳🇱Maastricht, Netherlands